That gap is the question this article addresses: not just how large it is, but why it exists, whether it matters clinically, and what it means for someone already on semaglutide today
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 (SGLT2) inhibitors are game-changers in the treatment of T2DM and are currently promoted by major clinical guidelines among potential first-line pharmacological options after failure/intolerance to metformin, especially in individuals with an atherosclerotic cardiovascular disease phenotype (GLP-1 RAs) [174]
So, Todd stayed on the drug
Our data suggest that reduced GSH synthesis rates and possibly increased irreversible utilization of glutathione contribute to its low concentration in type 2 diabetes
Performs best in formulas at pH 3.56 , with low oxygen/metal exposure
GHK-Cu (skin, hair, inflammation) Article: GHK-Cu studied for skin, hair and healing GHK-Cu is a naturally occurring copper-binding peptide discovered in human plasma that activates thousands of genes involved in healing, reducing inflammation, and protecting against oxidative stress
